Our client was working on the launch and market access strategy for a phase III oncology product.
Evidence collation, in the form of a Value Dossier, was also underway in preparation for HTA submissions and a global launch.
The objective of this project was to ensure appropriate and timely communication of key value messages for the product in preparation for the HTA submissions and global launch.
All relevant value messages and supporting evidence available were collated and prioritised based on their value to different stakeholders.
Journals and conferences offering optimal visibility for relevant messages were selected and categorised, based on prior coverage of similar topics, language, location, audience, impact factor, etc.
A timeline, including key milestones, was developed and followed throughout the course of the year to guarantee timely publication of all business-critical messages.
The client was able to plan ahead for all publications, using an annual publication plan covering key publications and conferences that were relevant.
This ensured that the necessary internal resources were available at the right time to deliver the materials needed for publication of all relevant messages through articles, abstracts and posters.
Key stakeholders were able to dedicate the time required to ensure smooth delivery of the publication plan at the most appropriate time to the right audience.